SERPINE2 feedback regulates EGF/EGFR signaling in human papillary thyroid carcinoma cells

Chu,Huimin; Hu,Bo; Su,Xinyu

doi:10.3892/mmr.2021.11981

SERPINE2 feedback regulates EGF/EGFR signaling in human papillary thyroid carcinoma cells

Authors:
- Huimin Chu
- Bo Hu
- Xinyu Su
View Affiliations

Affiliations: Department of Thyroid and Breast Surgery, The Central Hospital of Wuhan, Wuhan, Hubei 430014, P.R. China
Published online on: March 9, 2021 https://doi.org/10.3892/mmr.2021.11981
Article Number: 342

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Thyroid cancer (TC) is the most prevalent malignant tumor in the endocrine system. Serpin peptidase inhibitor clade E member 2 (SERPINE2) is closely associated with tumor metastasis. The aim of the present study was to investigate whether SERPINE2 forms a feedback loop with epidermal growth factor (EGF)/EGF receptor (EGFR) that regulates cellular processes in human papillary thyroid carcinoma (TPC‑1) cells. Reverse transcription‑quantitative PCR and western blotting were utilized to analyze the expression of SERPINE2. Cell proliferation ability was detected with a cell proliferation and cytotoxicity assay kit (MTT) and by clone formation assay. The proliferation markers, including proliferating cell nuclear antigen and Ki‑67, were also investigated to analyze the proliferative activity of TPC‑1 cells. Besides, cell migration and invasion were analyzed by wound healing and Transwell assays, respectively, while cell apoptosis was analyzed by TUNEL staining. The results showed that SERPINE2 expression was increased in TPC cells, and SERPINE2 and EGF/EGFR regulated each other. Furthermore, SERPINE2 overexpression and silencing regulated TPC cell proliferation, migration, invasion and apoptosis. Besides, an EGFR inhibitor blocked the effects of SERPINE2 overexpression on the aforementioned biological processes. Therefore, the present study confirmed that SERPINE2 formed a positive feedback with EGF/EGFR to regulate the proliferation, invasion and migration of TPC cells, possibly providing novel insights into potential therapeutic targets of papillary TC.

View Figures

View References

1	Bergeron S, Lemieux E, Durand V, Cagnol S, Carrier JC, Lussier JG, Boucher MJ and Rivard N: The serine protease inhibitor serpinE2 is a novel target of ERK signaling involved in human colorectal tumorigenesis. Mol Cancer. 9:2712010. View Article : Google Scholar : PubMed/NCBI
2	Wang K, Wang B, Xing AY, Xu KS, Li GX and Yu ZH: Prognostic significance of SERPINE2 in gastric cancer and its biological function in SGC7901 cells. J Cancer Res Clin Oncol. 141:805–812. 2015. View Article : Google Scholar : PubMed/NCBI
3	Zheng D, Gui B, Gray KP, Tinay I, Rafiei S, Huang Q, Sweeney CJ, Kibel AS and Jia L: Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer. Oncogene. 35:4807–4815. 2016. View Article : Google Scholar : PubMed/NCBI
4	Stępień T, Brożyna M, Kuzdak K, Motylewska E, Komorowski J, Stępień H and Ławnicka H: Elevated concentrations of SERPINE2/protease nexin-1 and secretory leukocyte protease inhibitor in the serum of patients with papillary thyroid cancer. Dis Markers. 2017:49621372017. View Article : Google Scholar : PubMed/NCBI
5	Monard D: SERPINE2/Protease Nexin-1 in vivo multiple functions: Does the puzzle make sense? Semin Cell Dev Biol. 62:160–169. 2017. View Article : Google Scholar : PubMed/NCBI
6	Nukiwa T, Suzuki T, Fukuhara T and Kikuchi T: Secretory leukocyte peptidase inhibitor and lung cancer. Cancer Sci. 99:849–855. 2008. View Article : Google Scholar : PubMed/NCBI
7	Valiente M, Obenauf AC, Jin X, Chen Q, Zhang XH, Lee DJ, Chaft JE, Kris MG, Huse JT, Brogi E and Massagué J: Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell. 156:1002–1016. 2014. View Article : Google Scholar : PubMed/NCBI
8	Wagenblast E, Soto M, Gutiérrez-Ángel S, Hartl CA, Gable AL, Maceli AR, Erard N, Williams AM, Kim SY, Dickopf S, et al: A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis. Nature. 520:358–362. 2015. View Article : Google Scholar : PubMed/NCBI
9	Konturek A, Barczyński M, Cichoń S, Pituch-Noworolska A, Jonkisz J and Cichoń W: Significance of vascular endothelial growth factor and epidermal growth factor in development of papillary thyroid cancer. Langenbecks Arch Surg. 390:216–221. 2005. View Article : Google Scholar : PubMed/NCBI
10	Xue L, Su D, Li D, Gao W, Yuan R and Pang W: MiR-200 regulates epithelial-mesenchymal transition in anaplastic thyroid cancer via EGF/EGFR signaling. Cell Biochem Biophys. 72:185–190. 2015. View Article : Google Scholar : PubMed/NCBI
11	Tang T, Zhu Q, Li X, Zhu G, Deng S, Wang Y, Ni L, Chen X, Zhang Y, Xia T, et al: Correction: Protease Nexin I is a feedback regulator of EGF/PKC/MAPK/EGR1 signaling in breast cancer cells metastasis and stemness. Cell Death Dis. 11:132020. View Article : Google Scholar : PubMed/NCBI
12	Zhang Z, Liu ZB, Ren WM, Ye XG and Zhang YY: The miR-200 family regulates the epithelial-mesenchymal transition induced by EGF/EGFR in anaplastic thyroid cancer cells. Int J Mol Med. 30:856–862. 2012. View Article : Google Scholar : PubMed/NCBI
13	Xu J, Zhang X, Wang H, Ge S, Gao T, Song L, Wang X, Li H, Qin Y and Zhang Z: HCRP1 downregulation promotes hepatocellular carcinoma cell migration and invasion through the induction of EGFR activation and epithelial-mesenchymal transition. Biomed Pharmacother. 88:421–429. 2017. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-DDct method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Wang D, Zheng X and Li M: Correlation analysis between the pre-operative contrast-enhanced ultrasound parameters and biological characteristics of papillary thyroid carcinoma and associated risk factors for prognosis after radiofrequency ablation. Exp Ther Med. 20:1575–1581. 2020. View Article : Google Scholar : PubMed/NCBI
16	Gupta S, Patel A, Folstad A, Fenton C, Dinauer CA, Tuttle RM, Conran R and Francis GL: Infiltration of differentiated thyroid carcinoma by proliferating lymphocytes is associated with improved disease-free survival for children and young adults. J Clin Endocrinol Metab. 86:1346–1354. 2001. View Article : Google Scholar : PubMed/NCBI
17	Barabadze E, Munjishvili V and Burkadze G: Braf antibody expression in different types of thyroid nodular lesions. Georgian Med News. 271:107–113. 2017.
18	Tang T, Zhu Q, Li X, Zhu G, Deng S, Wang Y, Ni L, Chen X, Zhang Y, Xia T, et al: Protease Nexin I is a feedback regulator of EGF/PKC/MAPK/EGR1 signaling in breast cancer cells metastasis and stemness. Cell Death Dis. 10:6492019. View Article : Google Scholar : PubMed/NCBI
19	D'Anneo A, Carlisi D, Emanuele S, Buttitta G, Di Fiore R, Vento R, Tesoriere G and Lauricella M: Parthenolide induces superoxide anion production by stimulating EGF receptor in MDA-MB-231 breast cancer cells. Int J Oncol. 43:1895–1900. 2013. View Article : Google Scholar : PubMed/NCBI
20	Su X, Shen Z, Yang Q, Sui F, Pu J, Ma J, Ma S, Yao D, Ji M and Hou P: Vitamin C kills thyroid cancer cells through ROS-dependent inhibition of MAPK/ERK and PI3K/AKT pathways via distinct mechanisms. Theranostics. 9:4461–4473. 2019. View Article : Google Scholar : PubMed/NCBI
21	Shen Y, Wang X, Xu J and Lu L: SerpinE2, a poor biomarker of endometrial cancer, promotes the proliferation and mobility of EC cells. Cancer Biomark. 19:271–278. 2017. View Article : Google Scholar : PubMed/NCBI
22	Akaishi J, Kondo T, Sugino K, Ogimi Y, Masaki C, Hames KY, Yabuta T, Tomoda C, Suzuki A, Matsuzu K, et al: Prognostic impact of the turin criteria in poorly differentiated thyroid carcinoma. World J Surg. 43:2235–2244. 2019. View Article : Google Scholar : PubMed/NCBI
23	Su JJ, Hui LZ, Xi CJ and Su GQ: Correlation analysis of ultrasonic characteristics, pathological type, and molecular markers of thyroid nodules. Genet Mol Res. 14:9–20. 2015. View Article : Google Scholar : PubMed/NCBI
24	Williamson T, Mendes TB, Joe N, Cerutti JM and Riggins GJ: Mebendazole inhibits tumor growth and prevents lung metastasis in models of advanced thyroid cancer. Endocr Relat Cancer. 27:123–136. 2020. View Article : Google Scholar : PubMed/NCBI
25	Bravo R, Frank R, Blundell PA and Macdonald-Bravo H: Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature. 326:515–517. 1987. View Article : Google Scholar : PubMed/NCBI
26	Kim JY, Kim KH, Lee WR, An HJ, Lee SJ, Han SM, Lee KG, Park YY, Kim KS, Lee YS and Park KK: Apamin inhibits PDGF-BB-induced vascular smooth muscle cell proliferation and migration through suppressions of activated Akt and Erk signaling pathway. Vascul Pharmacol. 70:8–14. 2015. View Article : Google Scholar : PubMed/NCBI
27	Sajeevan TP, Saraswathi TR, Ranganathan K, Joshua E and Rao UD: Immunohistochemical study of p53 and proliferating cell nuclear antigen expression in odontogenic keratocyst and periapical cyst. J Pharm Bioallied Sci. 6 (Suppl 1):S52–S57. 2014. View Article : Google Scholar : PubMed/NCBI
28	Yang D, Yao X, Zhou J, Zhou H, Lu G and Wang Y: Correlations of PCNA expression with thyroid cancer ultrasound and histopathologic features. Int J Clin Exp Pathol. 12:1378–1384. 2019.PubMed/NCBI
29	Cornianu M, Stan V, Lazăr E, Dema A, Golu I, Tăban S, Vlad M, Faur A, Vărcuş F and Babău F: Evaluation of proliferation potential in thyroid normo-/hypofunctioning and hyperfunctioning nodules. Rom J Morphol Embryol. 52:545–553. 2011.PubMed/NCBI
30	Pagliara V, Adornetto A, Mammì M, Masullo M, Sarnataro D, Pietropaolo C and Arcone R: Protease Nexin-1 affects the migration and invasion of C6 glioma cells through the regulation of urokinase plasminogen activator and matrix metalloproteinase-9/2. Biochim Biophys Acta. 1843:2631–2644. 2014. View Article : Google Scholar : PubMed/NCBI